Headlands Research announced its research centers have been selected to participate in numerous upcoming COVID-19 vaccine clinical trials.
Various Headlands sites have been selected for all currently announced late-stage COVID-19 vaccine trials, including, but not limited to, Phase/Stage II and III trials for Moderna and Pfizer. Recruitment efforts are actively underway at five of Headlands’ research sites, including: Atlanta, GA; McAllen, TX; Lake Charles, LA; Palm Beach, FL; and Houston, TX. Headlands sites are conducting over 15 Phase I-III COVID-19 trials across its network. The organization’s sites are fully technologically enabled through its eSource and eRegulatory functionality, allowing Headlands’ partners real-time access to patient data and ensuring maximum safety for monitoring staff.
“It has always been our mission and vision to profoundly impact the clinical trials process,” said Mark Blumling, CEO of Headlands Research. “We are excited to use our extensive vaccine experience during this pandemic while at the same time bringing COVID-19 studies to the ethnically diverse populations represented at our sites.”